e-ISSN:2320-1215 p-ISSN: 2322-0112

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Mini Review Open Access

Digitalization of the Pharmaceutical Industry with an Emphasis on Artificial Intelligence (AI) and Telemedicine

Abstract

Digitalization has significantly impacted the pharmaceutical industry, bringing about new and innovative ways to develop drugs, conduct clinical trials, and provide patient care. Two key technologies driving this transformation are Artificial Intelligence (AI) and telemedicine. AI algorithms and machine learning models are used for drug discovery, clinical decision-making, and patient monitoring. Telemedicine allows healthcare providers to remotely diagnose and treat patients, improving access to care and reducing costs. However, digitalization also presents challenges such as data privacy and security concerns, regulatory compliance, and the need for skilled professionals to manage the technology. The digital divide in healthcare access and technology infrastructure can also exacerbate existing inequalities in healthcare. The benefits of digitalization in the pharmaceutical industry with an emphasis on AI and telemedicine have the potential to transform healthcare and improve patient outcomes but require careful consideration and management of associated risks and challenges.

Pramathesh Mishra1*, Vivekanand Prajapati1, Shivendra Misra1, Shibani Panda

To read the full article Download Full Article | Visit Full Article